Thursday 05 September | 13:00 - 14:00
Lunchtime Symposia
Thursday 05 September | 13:00 - 14:00S. Wolf Switzerland F.G. Holz Germany
Welcome, opening audience response system questions
F.G. Holz Germany
Review of EURETINA delegate survey data to assess baseline trends
P. Dugel USA
Reviewing the various categories of retinal fluid and their impact on patient outcomes
S. Wolf Switzerland
Keys to accurately and consistently diagnosing fluid levels with multi-modal imaging
M. Zinkernagel Switzerland
Debate Side #1: Our goal with AMD patients should be to eliminate all retinal fluid to maximize outcomes
R. Tadayoni France
Debate Side #2: AMD patients can tolerate a small amount of SRF with no impact on visual outcome and it may be helpful in some patients
S. Wolf Switzerland F.G. Holz Germany
Panel Discussion: Why is “fluid-free” vs “residual fluid” a difficult outcome decision to make and what future diagnostics and treatments may help both sides of this debate?
Final ARS assessment and conclusion
Supported by:
The Great Fluid Debate: Reviewing Treatment Outcome Goals for the Wet AMD Patient
Moderator(s): S. Wolf Switzerland F.G. Holz Germany
P. Keane UK
Use of swept source OCT in challenging cases of central serous chorioretinopathy
C. Hoyng Netherlands
Morphological and topographical appearance of microaneurysms on swept-source OCTA
V. Papastefanou UK
Diabetic Retinopathy & Swept Source OCTAngio
A. Gaudric France
Topographic Variations of Choroidal Thickness in Healthy Eyes on Swept-Source Optical Coherence Tomography
Superior Visualization with Swept Source OCT and OCT Angiography
Moderator(s): P. Keane UK
J. Eells USA
Photobiomodulation for the treatment of retinal and optic nerve disease
K. Valter Australia
From bench to bedside – photobiomodulation in preclinical studies (an update)
M. Munk Switzerland
LIGHTSITE I: clinical analysis of the safety and efficacy of photobiomodulation in subjects with dry age-related macular degeneration
B. Burton UK
LIGHTSITE II: insights from the ongoing multi-center european clinical trial
Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases (An Update)
Moderator(s): J. Eells USA M. Munk Switzerland
B. Bodaghi France
Non-infectious uveitis affecting the posterior segment of the eye
M. Cordero Spain
NIU-PS: the unmet patient need
C. Pavesio UK
The 001 study: ILUVIEN for the prevention of relapse in recurrent NIU-PS
R. Khoramnia Germany
ILUVIEN real world data: experience from clinical practice
Q. Nguyen USA
Lessons learned in managing patients with uveitis: avoidance of cumulative damage
ILUVIEN for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Moderator(s): B. Bodaghi France Q. Nguyen USA
F. Behar-Cohen France
Unravelling the inflammation pathway
A. García-Layana Spain
Seeking consensus in DME management: findings from Spain
L. Kodjikian France
Key questions for managing DME in daily practice
H. Selen Kanar Turkey
Switch on, switch off: case series
Panelists:
A. Loewenstein Israel
B. Kuppermann US
F. Behar-Cohen France
A. García-Layana Spain
L. Kodjikian France
H. Selen Kanar Turkey
Discussion and Q&A
Transforming DME Clinical Practice
Moderator(s): A. Loewenstein Israel B. Kuppermann USA
Friday 06 September | 9:45 - 10:45
Morning Symposia
Friday 06 September | 9:45 - 10:45Welcome and introductions
L. Kodjikian France
T&E with Aflibercept: from design to dosing regimen
G. Cheung Singapore
Expanding the evidence: T&E in clinical practice
P. Kaiser USA
Panel discussion: let's discuss: the practicalities of T&E in the clinic
Moderated by: L. Kodjikian France
Panelists: G. Cheung Singapore
P. Kaiser USA
Summary and close
L. Kodjikian France
Keeping a Step Ahead of the Disease: Proactive Treatment for nAMD
Moderator(s): L. Kodjikian France
J-A. Sahel France
Welcome and introduction
B. Leroy Belgium
Starting with the end in mind: understanding the patient experience (interview with IRD patient)
M. Pennesi USA
Setting the scene: developing the first approved retinal gene therapy
B. Leroy Belgium
Patient selection: informing diagnosis through relevant testing
J-A. Sahel France
Retinal gene therapy in clinical practice: perspectives from an expert center
B. Leroy Belgium
Q&A
A New Vision in Retinal Gene Therapy: from Clinical Trials to Clinical Practice
Moderator(s): B. Leroy Belgium J-A. Sahel France
C. Orduna Spain
Experiences from 1 year navigated microsecond pulsing laser treatments in DME
N-A. Striebe Germany
Navigated microsecond pulsing treatment for central serous chorioretinopathy. A 100 cases review.
E. Di Carlo Germany
Short term efficacy and safety of navigated microsecond pulsing laser treatment in patients affected by macular edema after BRVO
J. Chhablani USA
Feasibility and study results of navigated microsecond pulsing peripheral laser treatment in diabetic retinopathy
Seeing the Invisible - Transparent Subthreshold Treatment with Navigated Microsecond Pulsing Laser
Moderator(s): G. Staurenghi Italy
Friday 06 September | 13:00 - 14:00
Lunchtime Symposia
Friday 06 September | 13:00 - 14:00R. Tadayoni France
Welcome
P. Schlottmann Argentina
Clinical value of treat & extend regimen and the RIVAL study
A. Koh Singapore
Changing clinical paradigm in DR
N. Eter Germany
A new horizon in ROP: the RAINBOW study
Panel Discussion
R. Tadayoni France
Summary and close
Ranibizumab; Retinal Care For all Ages: RIVAL (nAMD) to RAINBOW (ROP)
Moderator(s): R. Tadayoni France
F. Behar-Cohen France
Welcome and introductions
P. Kaiser USA
Design, binding, downstream effect
C.X.Y Qian
Could insights into drug dynamics inform patient management?
V. Chaudhary Canada
Consider this: should a stable retina drive the T&E regimen?
Moderated by: F. Behar-Cohen France
Panelists: P. Kaiser USA
C.X.Y Qian Canada
V. Chaudhary Canada
Let’s discuss: how does the evidence inform a proactive approach in clinical practice?
F. Behar-Cohen France
Summary of key learnings
Emerging Evidence: Molecular Properties and Patient Outcomes
Moderator(s): F. Behar-Cohen France
A. Augustin Germany
Inflammatory response and cytokines in DME
P. Udaondo Spain
Prognostic and predictive biomarkers: research meets clinical practice
F. Bandello Italy
Switch reality: preventing recurrence, preserving vision
Breaking the Cycle of Recurrence in DME: Where Research Meets Clinical Practice
Moderator(s): L. Kodjikian France
S. Sadda USA
Variability of the normal peripheral choroidal circulation
P. Stanga UK
International classification and guidelines for widefield imaging
T. Peto UK
Deep learning and artificial intelligence for diagnosing retinal disease
Take Another Look: Uncovering New Advances and Future Applications of Ultra-widefield
Moderator(s): T. Peto UK
H. Augustin Germany
Spotlight on the angiopoietin pathway
J. Monés Spain
Clinical evidence for the role of Ang-2 in retinal diseases
Illuminating the Role of Angiopoietins in Retinal Diseases
Moderator(s): J-F. Korobelnik France
G. Staurenghi Italy
The importance of multimodal imaging: the new NIDEK Mirante SLO/OCT platform
T. Ach Germany
SD-OCT and OCT-A scans: which, when, and why? Some practical aspects
S. Sadda USA
Retro mode imaging in AMD and macular dystrophies
New Mirante Multimodal Imaging and OCT-A Analytics Can Help Breakthrough Tricky Cases of Retinal Disorders
Moderator(s): G. Staurenghi Italy
R. Carvalho Portugal
The power of Stellaris Elite™ - taking performance further
E. Bali Belgium
Key learnings and surgical pearls with Vitesse™
Bausch + Lomb R&D team
How we’re raising the bar in retina innovation
Reimagine your Retina Surgery with Bausch + Lomb
Moderator(s): Y. Le Mer France
Saturday 07 September | 9:45 - 10:45
Morning Symposia
Saturday 07 September | 9:45 - 10:45R. Tadayoni France
Introduction and opening remarks
K. Al Sabti Kuwait
Go beyond 3D visualization
F. Devin France
Complex and VR surgical cases using the advanced features of the Constellation® Vision System
S. Rizzo Italy
Speed, flow, stability, access-the new HyperVit™ 20K vitrectomy Probe
M. Mura Saudi Arabia
27+® as go-to technology for challenging vitreoretinal cases
J.A. Pournaras Switzerland
Modern surgical management of vitreoretinal pathologies
N. Bechrakis Germany
Management of intraocular tumors with an advanced surgical system
The Vitreoretinal Procedure - Integration, Stability, Speed
Moderator(s): R. Tadayoni France
J-F. Korobelnik France
Welcome and introductions
A. Ambresin Switzerland
Pathogenesis of retinal vascular diseases
S. Sivaprasad UK
Optimizing patient management with early, intensive treatment
J-F Korobelnik France
Aflibercept in the real world: emerging data in DME
Moderated by: J-F Korobelnik France
Panelists: A. Ambresin Switzerland
S. Sivaprasad UK
Panel discussion: review of current recommendations and summary of key learnings
Unsurpassed Vision Gains and Optimized Patient Outcomes in DME
Moderator(s): J-F Korobelnik France
A. García-Layana Spain
Welcome and introduction
F. Bandello Italy
Unmet needs in the management of nAMD
L. Kodjikian France
The future of nAMD
M. Stumpp Switzerland
DARPin - a new approach to nAMD
M. De Smet Switzerland
What´s in the pipeline for patients?
nAMD Management: Beyond the Horizon
Moderator(s): F. Bandello Italy A. García-Layana Spain
N. Bressler USA
Chair’s introduction: advanced use of digital technology – examining the potential positive and negative impact on medical practice
A. Loewenstein Israel
Public health need for home monitoring in diabetic retinopathy and age-related macular degeneration
P. Keane UK
Application of deep learning systems for diabetic retinopathy and AMD in clinical practice
N. Bressler USA
The future of clinical trials and clinical practice
Applying Advanced Digital Technology in Practice
Moderator(s): N. Bressler USA
J. Monés Spain
The role of complement in geographic atrophy
U. Chakravaraty UK
Results from the FILLY phase 2 trial
I. Pearse UK
Evaluation of baseline characteristics on GA lesion progression in the FILLY trial
F.G. Holz Germany
Derby and Oaks phase 3 trials in GA
Complement C3 Inhibition in Geographic Atrophy
Moderator(s): F.G. Holz Germany
Saturday 07 September | 13:00 - 14:00
Lunchtime Symposia
Saturday 07 September | 13:00 - 14:00F.G. Holz Germany
Welcome and introduction
P. Kaiser USA
Challenges and opportunities in nAMD care
A. Koh Singapore
Moderated panel discussion
R. Hamilton UK
New therapy for nAMD: Updates from advanced clinical program
F.G. Holz Germany
Moderated panel discussion
F.G. Holz Germany
Closing comments
New Horizons in nAMD Treatment
Moderator(s): F.G. Holz Germany
P. Stalmans Belgium
First evidence for clinical trial of 27G vs 23G surgery
E. El Rayes Egypt
How innovation is making 27G a reality
C. Mazit France
Management of retinal detachment using 27g and a prospective randomised study comparing 25G vs 27G for the management of ERM and macular holes
F. Nerinckx Belgium
First experience with a new shorter 27G vitrectomy kit
Ready for Prime Time: Clinical Evidence of Advances in 27G Surgery
Moderator(s): P. Stalmans Belgium
A. García-Layana Spain
A. Minnella Italy
How to manage patients at risk of AMD with STARS questionnaire
A. Tufail UK
Artificial intelligence. Where do we go from here?
C. Creuzot-Garcher France
Diabetic retinopathy and OCT-A
D. Crabb UK
And what do people with AMD see?
Innovative Thinking in Retinal Disease
Moderator(s): J. Seddon USA
V. Chong UK
How retina lasers are different from each other?
A. Filloy Spain
Fovea-involving DME: reasons for the SubLiminal approach
L. Altay Germany
SubLiminal laser in CCSC management
L. Wu Costa Rica
Why SubLiminal laser should be favored vs PDT for CCSC treatment
V. Chong UK
New treatment perspectives and conclusion
Management of Retinal Diseases with SubLiminal Laser Therapy
Moderator(s): V. Chong UK
A. Loewenstein Israel
Outcomes in real-world settings and therapeutic advancements
P. Campochiaro USA
Continuous delivery: A future approach to nAMD management
Delivering the Future of nAMD Management
Moderator(s): R. Tadayoni France
J-F. Korobelnik France
Exploring new boundaries of OCT-A
G. Staurenghi Italy
Next generation of ultra-widefield angiography
G. Lang Germany
Integrated diagnostic imaging maximizing your diagnostic instruments
Retinal Imaging Advancements
Moderator(s): J-F. Korobelnik France